The Pleckstrin Homology Domain of Phospholipase C-{beta}2 as an Effector Site for Rac*

Jason T. Snyder {ddagger}, Alex U. Singer {ddagger}, Michele R. Wing {ddagger} §, T. Kendall Harden {ddagger} §  and John Sondek {ddagger} || ** {ddagger}{ddagger}

From the {ddagger}Department of Pharmacology, §Program in Neurobiology, ||Department of Biochemistry and Biophysics, **Program in Molecular and Cellular Biophysics, and {ddagger}{ddagger}Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, North Carolina 27599

Received for publication, February 10, 2003 , and in revised form, March 19, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Increasing evidence links the activation of Rho family GTPases to the stimulation of lipid hydrolysis catalyzed by phospholipase C (PLC)-{beta} isozymes. To better define this relationship, members of a library of recombinant Rho GTPases were screened for their capacity to directly engage various purified PLC-{beta} isozymes. Of the 17 tested members of the Rho family, only the active isoforms of Rac (Rac1, Rac2, and Rac3) both stimulate PLC-{beta} activity in vivo and bind PLC-{beta}2 and PLC-{beta}3, but not PLC-{beta}1, in vitro. Furthermore, the recognition site for Rac GTPases was localized to the pleckstrin homology (PH) domain of PLC-{beta}2, and this PH domain is fully sufficient to selectively interact with the active versions of the Rac GTPases, but not with other similar Rho GTPases. Together, these findings present a quantitative evaluation of the direct interactions between Rac GTPases and PLC-{beta} isozymes and define a novel role for the PH domain of PLC-{beta}2 as a putative effector site for Rac GTPases.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Phosphoinositide-specific phospholipase C (PLC)1-{beta} isoenzymes convert a variety of external stimuli into intracellular signaling events by hydrolyzing the minor membrane lipid component phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)-P2) into the second messengers inositol 1,4,5-trisphosphate and diacylglycerol (see Refs. 1 and 2). This important step in receptor-mediated signal transduction initiates an increase in cytoplasmic calcium ion levels and activates protein kinase C (3, 4). Whereas there are currently four distinct classes of phospholipase C isozymes ({beta}, {gamma}, {delta}, and {epsilon}), only the PLC-{beta} (2) and PLC-{epsilon} (5, 6) members are known to catalyze lipase activity in response to extracellular ligand binding to heptahelical, transmembrane G protein-coupled receptors (7).

The four known mammalian PLC-{beta} isozymes (PLC-{beta}1–4) are tightly regulated by G protein-coupled receptors via direct interactions with activated G{alpha}q (8, 9, 10) and G{beta}{gamma} subunits (11, 12, 13) of the heterotrimeric G protein family. Structural data from several PLC homologs suggests that PLC-{beta} isozymes possess a modular domain architecture containing an N-terminal pleckstrin homology (PH) domain adjacent to calcium-binding EF hand domains, followed by the catalytic {alpha}{beta} barrel domain, connected to a C2 domain, terminating with a C-terminal coiled-coil helical domain (14, 15, 16, 17). Whereas the C-terminal region unique to PLC-{beta} isozymes is required for engaging G{alpha}q (18), the binding surface of G{beta}{gamma} is less clear. Conflicting reports document the PH domain, a portion of the putative EF hands, and a region within the catalytic domain of PLC-{beta} as important for recognizing G{beta}{gamma} (19, 20, 21, 22, 23).

Both myristolated G{alpha}q and isoprenylated G{beta}{gamma} independently regulate PLC-{beta} at cellular membranes (24), where PLC-{beta} engages its phosphoinositide substrate, PtdIns(4,5)P2. Interestingly, PH domains from many proteins bind phosphoinositide membrane lipids (25), and for the case of PLC-{delta}, the PH domain recruits the enzyme to the lipid bilayer via specific interactions with PtdIns(4,5)P2 (26). Thus, whereas PLC-{beta} isozymes are soluble in aqueous solution, their regulation and catalytic function are intimately linked with membrane-associated heterotrimeric G protein subunits and particular membrane compositions, including specific lipid rafts (27).

The tacit assumption that inositol lipid signaling is solely regulated by heterotrimeric G proteins has grossly underestimated the complexity of PLC-{beta}-related signaling. Illenberger et al. (28, 29) have identified several members of the Rho family of small GTPases (Cdc42, Rac1, and Rac2) that stimulate PLC-{beta}-catalyzed inositol phosphate production. Rho GTPases comprise a major branch of the Ras superfamily of GTPases, and these oncogenic molecular switches are best known for their capacity to direct the organization of the actin cytoskeleton (30, 31). Regulation of PLC-{beta} by Rho GTPases appears to utilize portions of PLC-{beta} distinct from regions involved in promoting G{alpha}q and G{beta}{gamma} signaling (29). Furthermore, Rac2 also regulates the membrane association of PLC-{beta}2 (32), and a lipase-competent chimera of the putative PH domain of PLC-{beta}1 with the remaining portion of PLC-{beta}2 failed to respond to Rac stimulation and membrane recruitment (29).

The spectra of Rho GTPases that stimulate PLC-{beta} have not yet been defined. Moreover, whether Rho proteins and PLC-{beta} isozymes interact via direct protein-protein interactions, and which portions of PLC-{beta} are required for this activation are not yet known. To investigate the mechanism of activation of PLC-{beta} by Rho GTPases, a biosensor screen was developed to audition the Rho family GTPases for their capacity to directly recognize various full-length and truncated fragments of PLC-{beta} isozymes. This analysis reveals that PLC-{beta}2 and PLC-{beta}3 possess remarkable specificity for only the Rac members of the Rho family of GTPases, and these detected interactions are strictly dependent upon the activated, GTP-bound state of Rac. Importantly, the PH domain of PLC-{beta}2 is sufficient to engage Rac GTPases in an identical, nucleotide-specific manner with similar affinity. Thus, our findings quantify the direct interactions between PLC-{beta} isozymes and Rac GTPases and redefine the role of the PH domain of PLC-{beta}2 as fully competent to bind activated Rac GTPases.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Protein Production—The coding sequences for all known human Rho family GTPases (Fig. 1A) were amplified by PCR and ligated into NcoI/XhoI-digested pProExHTa. With the exception of RhoBTB1 and RhoBTB2, all Rho GTPase constructs were terminated at the site of C-terminal isoprenylation and substituted with serine for the cysteine normally isoprenylated. For the multidomain RhoBTB1 and RhoBTB2 proteins, only the putative Rho GTPase portions (residues 1–247) were produced. Escherichia coli strain BL21(DE3) cells were grown in LB broth until mid-log phase, and Rho proteins were induced from the pProExHTa vector with 0.5 mM isopropyl-1-thio-{beta}-D-galactopyranoside at either 30 °C for 6 h or 22 °C for 12 h. The soluble portion of the cellular lysate from each culture was applied to nickel-charged chelating Sepharose resin (Amersham Biosciences), and recombinant proteins were purified by immobilized metal ion affinity chromatography. Fractions rich in soluble, purified GTPase were dialyzed overnight against 20 mM Hepes (pH 7.5), 150 mM NaCl, 5% glycerol, and 5 mM MgCl2 and stored at -80 °C until needed. Guanosine 5'-O-(3-thiotriphosphate) (GTP{gamma}S) was loaded into GTPases as noted by incubation with 2 mM EDTA and a 10-fold molar excess of GTP{gamma}S (Sigma) for 30 min at 22 °C, before the above-mentioned dialysis step.



View larger version (39K):
[in this window]
[in a new window]
 
FIG. 1.
Biosensor screen to identify binding partners of the Rho GTPase family. A, dendrogram displaying the evolutionary relationship of the mammalian Rho family of small GTPases constructed from a sequence alignment of the Rho GTPases using Clustal X and NJ Plot (43). Cdc42(p) is the placental isoform of Cdc42. The italicized GTPases either did not express or produce soluble recombinant protein and were thus removed from the study. B, collection of purified Rho GTPases stained with Coomassie Brilliant Blue after SDS-PAGE. C, schematic displaying the biosensor screen to analyze the binding of Rho GTPases to PLC-{beta} isozymes. Purified Rho GTPase, loaded with either GTP{gamma}s or GDP, was injected individually in a random order over flow cells covalently cross-linked with specific PLC-{beta} isozymes, and binding was monitored using surface plasmon resonance as described under "Experimental Procedures." D, sensorgrams from injections (arrow) of 2 µM G{alpha}q with and without AlF4 (10 mM NaF, 30 µM AlCl3) over the PLC-{beta} surfaces. E, representative raw sensorgrams from the injections (arrows) of GTP{gamma}S-loaded Rho GTPases (5 µM) over the PLC-{beta}2 surface (red) and the blank control surface (black). Rho GTPase binding to the PLC-{beta}1 and PLC-{beta}3 surfaces was performed identical to that displayed for PLC-{beta}2. F, sensorgrams from injections (arrow) of GTP{gamma}S- and GDP-loaded Rac1 (10 µM) over the PLC-{beta} surfaces. Rac2 and Rac3 injections display trends (data not shown) identical to the data displayed for Rac1.

 

PCR-amplified fragments of the cDNAs encoding the PH domains of human PLC-{beta}2 (residues 1–144) and rat PLC-{delta} (residues 11–140) were subcloned into pProExHTa, expressed in E. coli strain BL21(DE3) cells until mid-log phase, and induced with 1 mM isopropyl-1-thio-{beta}-D-galactopyranoside for 3–5 h at 37 °C. PLC-{delta} PH domain was purified similar to the above-described Rho GTPase purification. PLC-{beta}2 PH domain was extracted from the pellet fraction of cellular lysate using 8 M urea, purified via immobilized metal ion affinity chromatography in 8 M urea, and eluted with an imidazole gradient in 8 M urea. Purified, unfolded PLC-{beta}2 PH domain was slowly dripped into 2 liters of 20 mM Tris (pH 7.5), 150 mM NaCl, 10% glycerol, and 500 mM L-arginine at 4 °C. Soluble, folded, monomeric PLC-{beta}2 PH domain was then isolated over a Sephacryl-200 gel filtration column (Amersham Biosciences) in 20 mM Tris (pH 7.5), 150 mM NaCl, and 5% glycerol and subsequently loaded onto Source S resin (Amersham Biosciences) in 20 mM MES (pH 6.0), 50 mM NaCl, and 5% glycerol and eluted with a linear NaCl gradient. The resulting purified PLC-{beta}2 PH domain is soluble at 20 mg/ml and, upon digestion of the His6 tag with tobacco etch virus (TEV) protease, readily crystallizes in 100 mM Tris (pH 7.5), 50 mM sodium acetate, and 20% polyethylene glycol 4000. The bacterial expression plasmid (pET28a) encoding the cDNA for the PH domain of {beta}-adrenergic receptor kinase 1 (residues 548–641, with six C-terminal histidines) was a generous gift from A. Bohm. {beta}-Adrenergic receptor kinase 1 PH domain was produced and purified by a method similar to that used for the Rho GTPase purification.

cDNAs for the coding regions of human G{alpha}q (residues 7–360), G{beta}1{gamma}2 subunits ({beta}1 = full-length, {gamma}2 = residues 1–68), and full-length human PLC-{beta}1, PLC-{beta}2, and PLC-{beta}3 were amplified by PCR and ligated into pFastBacHT. Baculovirus isolates were prepared following the Bac-to-Bac method (Invitrogen). Recombinant protein was expressed in High-Five insect cells for 48 h at 27 °C after infection with virus. G{beta}1 and G{gamma}2 baculovirus were co-infected at a molar ratio of unity. The resulting G{alpha}q and the G{gamma}2 polypeptides lack their known sites of post-translational modification. Insect cell-produced recombinant proteins were lysed using an Emulsi-Flex C5 (Avestin), extracted with 0.5% N-octyl-{beta}-gluco-pyranoside, purified by immobilized metal ion affinity chromatography as described above for the Rho GTPases, and cleaved with TEV protease until the His6 tag was completely removed. Proteins were further purified using the above-described gel exclusion and ion exchange purification steps used for the PH domain of PLC-{beta}2. The PH-C2 portion of PLC-{beta}2 (residues 1–801) is a proteolytic fragment of full-length PLC-{beta}2 protein that has been previously purified and characterized by others (29). PLC-{beta}2 PH-C2 was purified to homogeneity in a manner identical to that used for full-length PLC-{beta}2, except that no protease inhibitors were added. Matrix-assisted laser desorption ionization time-of-flight mass-spectral analysis from the University of North Carolina Chapel Hill Proteomics core facility revealed the boundary limits of the PH-C2 protein. The C-terminal domain (residues 871–1151) of PLC-{beta}2 has been characterized previously (17).

Fluorescence-based Nucleotide Exchange Assay—Verification of GTP loading by each recombinant Rho GTPase was accomplished using a previously described assay (33). Briefly, 2 µM Rho GTPase was incubated with 200 nM N-methylanthraniloyl-GTP (Biomol) for 300 s, and the change in relative fluorescence upon addition of 10 mM EDTA was monitored with a SpectraMax Gemini (Molecular Devices) at {lambda}ex = 360 nm, and {lambda}em = 440 nm. All soluble recombinant Rho GTPases displayed at least a 3-fold increase in the rate of nucleotide loading upon addition of EDTA.

Surface Plasmon Resonance—Rho GTPase binding was monitored using surface plasmon resonance with a BIAcore3000 (Biacore), at 25 °C, with flow rates of 20–25 µl/min, using Hepes-buffered saline with polysorbate 20 (supplemented with 5 mM MgCl2). For each experiment, equivalent immobilized protein surfaces were achieved for each flow cell on CM5 sensor chips (Biacore) by first activating each flow cell with an injection of a 1:1 mix of NHS/EDC. Each protein was captured on individual flow cells using injections of 0.2 mg/ml protein solutions followed by an injection of 1 M ethanolamine to block remaining active surface groups as described previously (34). For the screening of Rho GTPases, 8000–10,000 response units of proteins were attached to each sensor surface, whereas lower surface densities (1000–1500 response units) were created for the titration studies. Rho GTPases were injected in a random order over the sensor surfaces using kinjects of 20–35 µl, with buffer flowed over the sensor chip to promote dissociation of each GTPase with dissociation times extending to 1000 s. Rho GTPase proteins routinely completely dissociated from each sensor surface as judged by the stable response unit levels maintained for each flow cell over the course of the experiments. Thus, to preserve the integrity of the covalently immobilized proteins, no regeneration steps were performed. Unless noted, all sensorgrams were always normalized to the signal achieved due to binding a control "blank" flow cell surface. For kinetic evaluations, sensorgrams from each set of titrations were aligned, and the normalized data were globally fit to a 1:1 binding model (RI = 0) with BIAevaluation 3.2 software (Biacore). Resulting thermodynamic constants are the result of three independent sets of titrations.

Phospholipid binding was measured using a Biacore 2000 in a manner similar to the description above, with the following noted exceptions. Phospholipids were purchased from Biomol, dissolved in a 1:1 chloroform/methanol solution, dried under a nitrogen stream, and resuspended in Hepes-buffered saline (Biacore) by sonication. His6-tagged PLC-{beta}2 PH domain was attached to a CM5 chip (Biacore) coated with covalently attached anti-penta-histidine antibody (Qiagen) and washed with buffer to remove nonspecific binding before phospholipid injections were performed. Between lipid injections, the PLC-{beta}2 PH domain surface was regenerated with a pulse of 1 M imidazole before immobilizing fresh protein.

COS-7 Cell Transfections and Phospholipase C-{beta} Activity Measurements—pcDNA3.1 vectors (Invitrogen) encoding Rho GTPases activated with a G12V mutation and fused to hemagglutinin tags were obtained from the Guthrie cDNA Resource Center. G{beta}1, G{gamma}2, and G{alpha}q pcDNA vectors have been described previously (35). COS-7 cells were seeded in 12-well culture dishes at a density of ~60,000 cells/well and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at 37 °C in an atmosphere of 90% air/10% CO2. The indicated DNA vectors were transfected using FuGENE 6 (Roche Applied Science) transfection reagent (3 µl FuGENE 6/1 µg DNA) according to the manufacturer's protocol. Six hundred ng total DNA/well was transfected, with empty vector added as necessary to maintain an equal amount of DNA for each well. Approximately 24 h after transfection, media were removed and replaced with myo-[3H]inositol (1 µCi/well) in inositol-free Dulbecco's modified Eagle's medium. After 12 h, [3H]inositol phosphate accumulation was initiated by addition of LiCl to a final concentration of 10 mM. The reaction was stopped after 1 h by aspiration of the medium and addition of 50 mM formic acid followed by neutralization with 150 mM NH4OH. [3H]Inositol phosphates were quantified by Dowex chromatography as described previously (36).


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Biosensor GTPase Screen—To define the spectrum of Rho family GTPases that directly bind PLC-{beta} isozymes, 17 recombinant Rho GTPases were produced and purified (Fig. 1, A and B). Each purified GTPase is indeed functional because these Rho proteins all exhibit the capacity to load guanine nucleotides (see "Experimental Procedures") (37). Specifically, the integrity of the Cdc42 protein was further validated by demonstrating that intersectin, a known Cdc42-specific guanine nucleotide exchange factor, but not Tiam1, a Rac1-specific exchange factor, will stimulate removal of bound nucleotide within Cdc42 as described previously (33).

Full-length PLC-{beta}1, PLC-{beta}2, and PLC-{beta}3 were immobilized to individual flow cells on a Biacore CM5 sensor chip as a means to identify GTPases that directly interact with PLC-{beta} isozymes using surface plasmon resonance (Fig. 1C). To verify the integrity of each immobilized PLC-{beta} surface, we demonstrated that, as reported previously (24), an active form of G{alpha}q (GDP + AlF4), but not inactive G{alpha}q (GDP), specifically binds to each PLC-{beta} isozyme (Fig. 1D). For each Rho GTPase displayed in Fig. 1B, both the active (GTP{gamma}S-loaded) and inactive (GDP-loaded) states were screened for binding to each PLC-{beta} surface (Fig. 1E). Surprisingly, only GTP{gamma}S-loaded Rac GTPases (Rac1, Rac2, and Rac3), but no other tested Rho protein, displayed differential binding to the PLC-{beta} surfaces compared with a blank control surface. Moreover, the activated Rac GTPases, but not the GDP-loaded forms, exhibited an observed specificity for PLC-{beta}2 and PLC-{beta}3, with no detectable binding to PLC-{beta}1 (Fig. 1F). These data suggest that Rac1, Rac2, and Rac3, but not other members of the highly conserved Rho family of GTPases, can directly interact with PLC-{beta} isozymes in a nucleotide-specific manner.

In Vivo PLC-{beta}2 Stimulation by Rac GTPases—The capacity of Rac GTPases to specifically stimulate PLC-{beta}2-catalyzed inositol phosphate formation in COS-7 cells was next evaluated (Fig. 2). As expected, increasing amounts of cDNA for G{alpha}q (Fig. 2A) and G{beta}1{gamma}2 (Fig. 2B) both stimulated inositol phosphate accumulation, but only after co-transfection with PLC-{beta}2. Significantly, and in a fashion consistent with our surface plasmon resonance biosensor screen, constitutively active GTPase-deficient Rac1 (Fig. 2C), Rac2 (Fig. 2D), and Rac3 (Fig. 2E) G12V mutants (38) considerably enhanced the lipase activity of PLC-{beta}2. In contrast, constitutively active Cdc42 (G12V) failed to stimulate detectable inositol phosphate accumulation (Fig. 2F) despite being expressed to significant levels. These data indicate that the capacity of Rac GTPases to stimulate PLC-{beta}2 activity in vivo is not shared by Cdc42 and are consistent with the lack of observable binding between Cdc42 and the PLC-{beta} isozymes tested using surface plasmon resonance.



View larger version (37K):
[in this window]
[in a new window]
 
FIG. 2.
Specific stimulation of PLC-{beta}2 by Rac GTPases. COS-7 cells were transfected with increasing amounts (0–300 ng) of pcDNA encoding (A) G{alpha}q, (B) G{beta}1{gamma}2, (C) Rac1 G12V, (D) Rac2 G12V, (E) Rac3 G12V, (F) Rac3 G12V, and either 300 ng of PLC-{beta}2 DNA (•) or 300 ng of empty vector ({square}). The resulting [3H]inositol phosphate accumulation was quantified as described under "Experimental Procedures." Insets display Western blot analysis of the expression levels of each noted GTPase with the indicated amounts of transfected GTPase DNA using anti-hemagglutinin-peroxidase antibody (Roche Applied Science). Data shown are the mean ± S.D. for duplicate samples.

 

Quantification of Affinities between Rac GTPases and PLC-{beta} Isozymes—To quantify interactions between recombinant Rac GTPases and PLC-{beta}2 and PLC-{beta}3, a concentration series of each Rac GTPase (loaded with GTP{gamma}S) was injected across the immobilized PLC-{beta} isozyme surfaces using Biacore technology (Fig. 3, A and B). The resulting sensorgrams display concentration-dependent binding events between the Rac GTPases and PLC-{beta}2 and PLC-{beta}3. To estimate the dissociation constants for these interactions, the steady state equilibrium responses (Req) were plotted against Rac concentration and fit to simple binding isotherms (39) (Fig. 3C). As displayed in Table I, Rac1, Rac2, and Rac3 each bind PLC-{beta}2 (KD = 5–10 µM) with greater affinity than PLC-{beta}3 (KD > 25 µM) and display no detectable binding to PLC-{beta}1 at concentrations of up to 50 µM GTPase.



View larger version (21K):
[in this window]
[in a new window]
 
FIG. 3.
Representative data sets for the analysis of Rac3-GTP{gamma}S interacting with PLC-{beta} isozymes. A and B, sensorgrams from titrations of Rac3-GTP{gamma}S (0.05, 0.1, 0.25, 1, 5, 10, 25, and 50 µM) injected over PLC-{beta}2 (A) and PLC-{beta}3 (B) surfaces. Dashed lines indicate the global fits obtained from a 1:1 interaction model, A + B = AB, and arrows indicate interval of injections. C, plots of the steady state equilibrium binding signal against the concentration of Rac3-GTP{gamma}S fit to a binding isotherm for each indicated PLC-{beta} interaction. Estimated dissociation constants from these titrations and also for the Rac1 and Rac2 titrations are presented in Table I.

 

View this table:
[in this window]
[in a new window]
 
TABLE I
Dissociation constants for the Rac-GTP{gamma}S/PLC-{beta} interactions

KD values (µM) were estimated from best fits of surface plasmon resonance titration data as presented in Figs. 3 and 5. NB (no binding) indicates a lack of saturable binding for the highest concentration of GTPase (50 µM) examined. Each dissociation constant is the mean of several experiments with the errors cited as S.D.

 



View larger version (36K):
[in this window]
[in a new window]
 
FIG. 5.
The PH domain of PLC-{beta}2 selectively binds GTP{gamma}S-loaded Rac GTPases. A, schematic of the domain boundaries of full-length (FL) PLC-{beta}2 (PH domain, EF hands, catalytic domain, C2 domain, and the C-terminal domain) and the produced recombinant PLC-{beta}2 protein fragments. B and C display representative sensorgrams from injections of GTP{gamma}S-loaded Rac3 and RhoA, respectively, over surfaces composed of the indicated portions of PLC-{beta}2. Each Rho GTPase was injected over the sensor chip as described for Fig. 1. D and E display representative sensorgrams from injections of 5 µM G{beta}1{gamma}2 and 2.5 µM Rac3-GTP{gamma}S, respectively, over surfaces composed of the indicated PH domains. F, representative sensorgrams from injections of Rac3-GTP{gamma}S, Rac3-GDP, and Cdc42-GTP{gamma}S over the identical PLC-{beta}2 PH domain surface. G, a titration series of Rac1-GTP{gamma}S over a low density PLC-{beta}2 PH domain surface as described in Fig. 3A.

 
Phosphoinositide Binding by the PLC-{beta}2 PH Domain—Previous studies implicate the PH domain of PLC-{beta}2 as important for Rac-mediated stimulation of PLC-{beta}2 (29, 32). Thus, we produced and assessed the functional properties of the isolated PH domain of PLC-{beta}2. Because the most attributed biochemical function of PH domains is their capacity to bind phosphoinositides (25), the lipid binding properties of the PLC-{beta}2 PH domain were examined using micelles composed of individual phospholipids. Significantly, the PLC-{beta}2 PH domain preferably bound PtdIns(4,5)P2 and phosphatidylinositol 4-phosphate over other negatively charged membrane lipids, phosphatidylinositol and dipalmitoyl phosphatidylserine (Fig. 4A). Therefore, as observed for the majority of the previously characterized PH domains (40), the PLC-{beta}2 PH domain promiscuously binds various phosphoinositides with no significant binding to other phospholipids. The estimated dissociation constant is ~15 µM for the interaction of PtdIns(4,5)P2 and the PH domain of PLC-{beta}2 (Fig. 4B). These data indicate that the refolded PH domain from PLC-{beta}2 is biochemically functional and suitable as a target for assessing the binding of Rho GTPases.



View larger version (22K):
[in this window]
[in a new window]
 
FIG. 4.
The PH domain of PLC-{beta}2 selectively recognizes phosphoinosotides over other membrane lipids. A, representative sensorgrams from injections (arrow) of indicated lipids over a biosensor surface containing the PH domain of PLC-{beta}2. B, titration of micelles containing PtdIns(4,5)P2 injected over a biosensor surface bound to the PH domain of PLC-{beta}2. The estimated dissociation constant (KD) for this interaction is 15 µM.

 

Rac GTPase Binding by the PLC-{beta}2 PH Domain—To define the region of PLC-{beta} that is sufficient to recognize activated Rac GTPases, several soluble fragments of PLC-{beta}2 were generated (Fig. 5A). These include the C-terminal domain, a fragment spanning the PH and C2 domains, and the above-mentioned isolated PH domain. The capacity of the PLC-{beta}2 fragments to recognize Rac GTPases was analyzed via surface plasmon resonance. Whereas the C-terminal fragment of PLC-{beta}2 did not bind any of the Rho GTPases from our recombinant library, the isolated PH domain and the PH-C2 protein both mimicked the binding characteristics of full-length PLC-{beta}2 by interacting with GTP{gamma}S-loaded Rac GTPases (Fig. 5B), but not with GTP{gamma}S-loaded RhoA (Fig. 5C) or any of the other screened Rho proteins (Fig. 1B). Titration experiments revealed that the PH domain and the PH-C2 proteins bound Rac-GTP{gamma}S isoforms (KD =10–20 µM) with affinities comparable to the full-length PLC-{beta}2 (KD = 5–10 µM) (Table I). In contrast, the C-terminal domain, which has been shown to be properly folded by circular dichroism (17), did not bind Rac or any other Rho family GTPase.

To further verify the specific interaction of activated Rac GTPases with the isolated PH domain of PLC-{beta}2, Rac binding to a set of similar PH domains was compared. Equivalent surface levels of purified PH domains from the {beta}-adrenergic receptor kinase 1, PLC-{delta}, and PLC-{beta}2 were created. Injections of G{beta}1{gamma}2 resulted in a robust binding signal for the PH domain of {beta}-adrenergic receptor kinase 1 relative to the PH domains of PLC-{delta} and PLC-{beta}2 (Fig. 5D). This observation confirms that the {beta}-adrenergic receptor kinase 1 PH domain is functional and competent to engage G{beta}1{gamma}2 as described previously (41). The weak signal observed for G{beta}1{gamma}2 binding to the PLC-{delta} and PLC-{beta}2 PH domains did not increase with increasing G{beta}1{gamma}2 concentrations and is thus likely to be nonspecific (data not shown). Using this same system, Rac-GTP{gamma}S isoforms displayed remarkable specificity for the PH domain of PLC-{beta}2 over the highly homologous PLC-{delta} and {beta}-adrenergic receptor kinase 1 PH domains (Fig. 5E). The PH domain of PLC-{beta}2 was highly selective for Rac-GTP{gamma}S over Rac-GDP and all other tested Rho proteins in either nucleotide state (Fig. 5F). All three GTP{gamma}S-loaded Rac isoforms bound the PLC-{beta}2 PH domain in a similar concentration-dependent manner with an estimated dissociation constant of ~13 µM for the Rac1 interaction (Fig. 5G). Therefore, although the PH domain of PLC-{beta}2 does not display significant binding to G{beta}1{gamma}2, it is sufficient to selectively engage Rac1, Rac2, and Rac3 in a nucleotide-dependent manner.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
This study defines Rac1, Rac2, and Rac3 as the sole members of the highly conserved family of Rho GTPases capable of directly engaging PLC-{beta}2 and PLC-{beta}3 isozymes in a GTP{gamma}S-dependent manner. Our in vitro direct binding and in vivo transfection approaches both concur in specifically distinguishing only the Rac isoforms as modulators of PLC-{beta}. Quantitative affinity measurements clearly delineate all three Rac GTPases as similar in their differential ability to recognize PLC-{beta}2 > PLC-{beta}3 > PLC-{beta}1. This trend mimics the pattern of PLC-{beta} stimulation observed with Rac1 and Rac2 by others (29). Moreover, our findings demonstrate that both PLC-{beta}2 and PLC-{beta}3 bind the very similar Rac isoforms with comparable affinities, with no observed binding to GDP-loaded GTPases. Previous reports identified Cdc42, Rac1, and Rac2 as stimulators of PLC-{beta} activity (28, 42). In contrast, Cdc42 does not interact with PLC-{beta}2 as measured by surface plasmon resonance (Fig. 1E), and we have been unable to observe enhanced lipase activity upon co-transfection of activated Cdc42 with PLC-{beta}2 (Fig. 2F). Whereas interactions between Cdc42 and PLC-{beta} isozymes were not detected in this study, Illenberger et al. (29) reported that Cdc42 stimulated PLC-{beta}2 10-fold less efficiently than Rac2. Thus, it is plausible that our biosensor assay is insufficiently sensitive to detect weak binding of Cdc42. None-theless, the in vivo stimulation of PLC-{beta}2 by Cdc42 appears insignificant relative to activation by Rac GTPases.

An important outcome of this analysis is the delineation of the PH domain of PLC-{beta}2 as sufficient for binding Rac GTPases. The isolated PH domain differentially recognizes GTP{gamma}S-loaded Rac1, Rac2, and Rac3 over the GDP-loaded Rac isoforms and all other screened Rho proteins in either nucleotide state. Thus, the isolated PH domain of PLC-{beta}2 mimics the full-length enzyme in selectively binding the activated forms of Rac with dissociation constants of ~5–10 µM. This finding coincides with the capacity of a previously designed chimera of PLC-{beta}2 containing a substituted PH domain from PLC-{beta}1 to retain lipase activity yet fail to respond to GTP{gamma}S-loaded Rac2 (29).

Whereas we readily detect binding of G{beta}{gamma} to the PH domain of {beta}-adrenergic receptor kinase 1 using surface plasmon resonance, G{beta}{gamma} does not display significant affinity for the PH domains of PLC-{beta}2 or PLC-{delta} under similar conditions. This observation directly conflicts with previous studies showing lateral association of fluorescence-tagged PH domains of PLC-{beta} and PLC-{delta} with G{beta}{gamma} in lipid vesicles (21). However, it must be noted that these previous studies used larger fragments (e.g. 1–171 of PLC-{beta}2 and 1–155 of PLC-{delta}) that also encompass portions of the first EF hand. Therefore, the discrepancies in binding may result from different fragment sizes. Alternatively, potential interactions of G{beta}{gamma} with PH domains of PLC-{beta} and PLC-{delta} isozymes are sufficiently weak, such that we are unable to detect these interactions using surface plasmon resonance. Therefore, the increased effective concentrations afforded by sequestering the binding partners to a two-dimensional lipid membrane may be necessary to observe these interactions (21). A strong mechanistic consequence of the interaction between the PH domain of {beta}-adrenergic receptor kinase 1 and G{beta}{gamma} has been defined (41, 44). In contrast, G{beta}{gamma} has been demonstrated to bind a plethora of PH domains from diverse signaling molecules, including the PH domain of PLC-{beta} (21, 45, 46, 47, 48); however, the functional significance of these interactions is still unclear.

These studies also demonstrate a clear selectivity of the PH domain of PLC-{beta}2 for phosphoinositides over other negatively charged lipid components. This observation classifies the PLC-{beta}2 PH domain as similar to the majority of characterized PH domains that also have weak, promiscuous interactions with various phosphoinositides (40). However, both isolated PH domains from PLC-{beta} isozymes and the full-length enzymes target to lipid vesicles independent of phosphoinositide composition (21, 49). Thus, whereas PH domains from PLC-{beta} isozymes and other membrane-associated proteins (Dbl family guanine nucleotide exchange factors) recognize phosphoinositides (50), these interactions are insufficient to target the host proteins to the cellular membrane (49, 51).

Despite the uncertain functional roles of PLC-{beta} PH domains in recognizing G{beta}{gamma} and phosphoinositides (52), this study clearly defines the PH domain of PLC-{beta}2 as a binding site and perhaps an effector site for Rac GTPases. Whereas PLC-{beta} has no recognized CRIB motif common to well-understood Rho GTPase effectors (p21 activated kinase, ACK, and Wiskott Aldrich syndrome protein) (53, 54, 55), several lines of evidence provide a precedent for GTPases directly engaging PH domains. For instance, a recent report documents the direct binding of RhoA to the Btk family tyrosine kinase Etk through the N-terminal PH domain of the kinase (56). Additionally, Wittinghofer and colleagues (57) have determined the co-crystal structure of the active form of the small GTPase Ran bound to a Ran-binding domain of RanBP2. Importantly, the three-dimensional architecture of this Ran-binding domain is a {beta}-barrel sandwich capped with a C-terminal helix, closely resembling the canonical PH domain fold observed for all visualized PH domain structures (58). Thus, Rac GTPases engaging PLC-{beta} PH domains could mimic this documented structural configuration.

Many questions remain regarding the integrated regulation of PLC-{beta} isozymes by heterotrimeric G proteins and small Ras-like GTPases. For instance, whereas it seems extremely likely that PLC-{beta}2 is an in vivo effector of activated Rac GTPases through direct interactions mediated by the PH domain, this connection has yet to be implicated directly in specific signaling cascades. Regardless, our results define the spectrum of Rho GTPases that specifically recognize individual PLC-{beta} isozymes, quantify the abilities of these GTPases to bind PLC-{beta}, and demonstrate that the PH domain of PLC-{beta}2 is sufficient to engage active Rac GTPases. The in vivo signaling cascades modulated by activate Rac GTPases operating on PLC-{beta} isozymes, especially PLC-{beta}2, await future studies.


    FOOTNOTES
 
* This work was supported by National Institutes of Health Grants GM62299 and GM57391 (to J. S.) and GM65533 and GM29536 (to T. K. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Dept. of Pharmacology, University of North Carolina, CB #7365, 1106 M. E. J. Bldg., Chapel Hill, NC 27599. Tel.: 919-966-4816; E-mail: tkh{at}med.unc.edu.

1 The abbreviations used are: PLC, phospholipase C; PtdIns(4,5)P2, phosphatidylinositol 4,5-bisphosphate, PH, pleckstrin homology; GTP{gamma}S, guanosine 5'-O-(3-thiotriphosphate); MES, 4-morpholine-ethanesulfonic acid. Back


    ACKNOWLEDGMENTS
 
We thank M. Pham and S. Gershburg for help with protein production.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Rebecchi, M. J., and Pentyala, S. N. (2000) Physiol. Rev. 80, 1291-1335[Abstract/Free Full Text]
  2. Rhee, S. G. (2001) Annu. Rev. Biochem. 70, 281-312[CrossRef][Medline] [Order article via Infotrieve]
  3. Berridge, M. J. (1984) Biochem. J. 220, 345-360[Medline] [Order article via Infotrieve]
  4. Burgess, G. M., Godfrey, P. P., McKinney, J. S., Berridge, M. J., Irvine, R. F., and Putney, J. W., Jr. (1984) Nature 309, 63-66[Medline] [Order article via Infotrieve]
  5. Kelley, G. G., Reks, S. E., Ondrako, J. M., and Smrcka, A. V. (2001) EMBO J. 20, 743-754[Abstract/Free Full Text]
  6. Wing, M. R., Houston, D., Kelley, G. G., Der, C. J., Siderovski, D. P., and Harden, T. K. (2001) J. Biol. Chem. 276, 48257-48261[Abstract/Free Full Text]
  7. Smith, C. D., Cox, C. C., and Snyderman, R. (1986) Science 232, 97-100[Medline] [Order article via Infotrieve]
  8. Taylor, S. J., Chae, H. Z., Rhee, S. G., and Exton, J. H. (1991) Nature 350, 516-518[CrossRef][Medline] [Order article via Infotrieve]
  9. Smrcka, A. V., Hepler, J. R., Brown, K. O., and Sternweis, P. C. (1991) Science 251, 804-807[Medline] [Order article via Infotrieve]
  10. Waldo, G. L., Boyer, J. L., Morris, A. J., and Harden, T. K. (1991) J. Biol. Chem. 266, 14217-14225[Abstract/Free Full Text]
  11. Camps, M., Hou, C., Sidiropoulos, D., Stock, J. B., Jakobs, K. H., and Gierschik, P. (1992) Eur. J. Biochem. 206, 821-831[Abstract]
  12. Boyer, J. L., Waldo, G. L., and Harden, T. K. (1992) J. Biol. Chem. 267, 25451-25456[Abstract/Free Full Text]
  13. Blank, J. L., Brattain, K. A., and Exton, J. H. (1992) J. Biol. Chem. 267, 23069-23075[Abstract/Free Full Text]
  14. Heinz, D. W., Ryan, M., Bullock, T., and Griffith, O. H. (1995) EMBO J. 14, 3855-3863[Abstract]
  15. Ferguson, K. M., Lemmon, M. A., Schlessinger, J., and Sigler, P. B. (1995) Cell 83, 1037-1046[Medline] [Order article via Infotrieve]
  16. Essen, L., Perisic, O., Cheung, R., Katan, M., and Williams, R. L. (1996) Nature 380, 595-602[CrossRef][Medline] [Order article via Infotrieve]
  17. Singer, A. U., Waldo, G. L., Harden, T. K., and Sondek, J. (2002) Nat. Struct. Biol. 9, 32-36[CrossRef][Medline] [Order article via Infotrieve]
  18. Paulssen, R. H., Woodson, J., Liu, Z., and Ross, E. M. (1996) J. Biol. Chem. 271, 26622-26629[Abstract/Free Full Text]
  19. Kuang, Y. N., Wu, Y. Q., Smrcka, A., Jiang, H. P., and Wu, D. Q. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2964-2968[Abstract/Free Full Text]
  20. Sankaran, B., Osterhout, J., Wu, D., and Smrcka, A. V. (1998) J. Biol. Chem. 273, 7148-7154[Abstract/Free Full Text]
  21. Wang, T., Pentyala, S., Rebecchi, M. J., and Scarlata, S. (1999) Biochemistry 38, 1517-1524[CrossRef][Medline] [Order article via Infotrieve]
  22. Barr, A. J., Ali, H., Haribabu, B., Snyderman, R., and Smrcka, A. V. (2000) Biochemistry 39, 1800-1806[CrossRef][Medline] [Order article via Infotrieve]
  23. Wang, T., Dowal, L., El-Maghrabi, M. R., Rebecchi, M., and Scarlata, S. (2000) J. Biol. Chem. 275, 7466-7469[Abstract/Free Full Text]
  24. Runnels, L. W., and Scarlata, S. F. (1999) Biochemistry 38, 1488-1496[CrossRef][Medline] [Order article via Infotrieve]
  25. Lemmon, M. A., and Ferguson, K. M. (2000) Biochem. J. 350, 1-18[CrossRef][Medline] [Order article via Infotrieve]
  26. Garcia, P., Gupta, R., Shah, S., Morris, A. J., Rudge, S. A., Scarlata, S., Petrova, V., McLaughlin, S., and Rebecchi, M. J. (1995) Biochemistry 34, 16228-16234[Medline] [Order article via Infotrieve]
  27. Scarlata, S. (2002) Biochemistry 41, 7092-7099[CrossRef][Medline] [Order article via Infotrieve]
  28. Illenberger, D., Schwald, F., Pimmer, D., Binder, W., Maier, G., Dietrich, A., and Gierschik, P. (1998) EMBO J. 17, 6241-6249[Abstract/Free Full Text]
  29. Illenberger, D., Walliser, C., Nurnberg, B., Diaz Lorente, M., and Gierschik, P. (2003) J. Biol. Chem. 278, 3006-3014[Abstract/Free Full Text]
  30. Hall, A. (1998) Science 279, 509-514[Abstract/Free Full Text]
  31. Etienne-Manneville, S., and Hall, A. (2002) Nature 420, 629-635[CrossRef][Medline] [Order article via Infotrieve]
  32. Illenberger, D., Walliser, C., Strobel, J., Gutman, O., Niv, H., Gaidzik, V., Kloog, Y., Gierschik, P., and Henis, Y. I. (2003) J. Biol. Chem. 278, 8645-8652[Abstract/Free Full Text]
  33. Snyder, J. T., Worthylake, D. K., Rossman, K. L., Betts, L., Pruitt, W. M., Siderovski, D. P., Der, C. J., and Sondek, J. (2002) Nat. Struct. Biol. 9, 468-475[CrossRef][Medline] [Order article via Infotrieve]
  34. Day, Y. S., Baird, C. L., Rich, R. L., and Myszka, D. G. (2002) Protein Sci. 11, 1017-1025[Abstract/Free Full Text]
  35. Blake, B. L., Wing, M. R., Zhou, J. Y., Lei, Q., Hillmann, J. R., Behe, C. I., Morris, R. A., Harden, T. K., Bayliss, D. A., Miller, R. J., and Siderovski, D. P. (2001) J. Biol. Chem. 276, 49267-49274[Abstract/Free Full Text]
  36. Brown, H. A., Lazarowski, E. R., Boucher, R. C., and Harden, T. K. (1991) Mol. Pharmacol. 40, 648-655[Abstract]
  37. Remmers, A. E., Posner, R., and Neubig, R. R. (1994) J. Biol. Chem. 269, 13771-13778[Abstract/Free Full Text]
  38. Krengel, U., Schlichting, L., Scherer, A., Schumann, R., Frech, M., John, J., Kabsch, W., Pai, E. F., and Wittinghofer, A. (1990) Cell 62, 539-548[Medline] [Order article via Infotrieve]
  39. Myszka, D. G. (1997) Curr. Opin. Biotechnol. 8, 50-57[CrossRef][Medline] [Order article via Infotrieve]
  40. Kavran, J. M., Klein, D. E., Lee, A., Falasca, M., Isakoff, S. J., Skolnik, E. Y., and Lemmon, M. A. (1998) J. Biol. Chem. 273, 30497-30508[Abstract/Free Full Text]
  41. Pitcher, J. A., Touhara, K., Payne, E. S., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 11707-11710[Abstract/Free Full Text]
  42. Illenberger, D., Schwald, F., and Gierschik, P. (1997) Eur. J. Biochem. 246, 71-77[Abstract]
  43. Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F., and Higgins, D. G. (1997) Nucleic Acids Res. 25, 4876-4882[Abstract/Free Full Text]
  44. Touhara, K., Koch, W. J., Hawes, B. E., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 17000-17005[Abstract/Free Full Text]
  45. Abrams, C. S., Zhao, W., and Brass, L. F. (1996) Biochim. Biophys. Acta 1314, 233-238[CrossRef][Medline] [Order article via Infotrieve]
  46. Xu, N., Coso, O., Mahadevan, D., De Blasi, A., Goldsmith, P. K., Simonds, W. F., and Gutkind, J. S. (1996) Cell. Mol. Neurobiol. 16, 51-59[Medline] [Order article via Infotrieve]
  47. Sawai, T., Hirakawa, T., Yamada, K., and Nishizawa, Y. (1999) Biol. Pharm. Bull. 22, 229-233[Medline] [Order article via Infotrieve]
  48. Mahadevan, D., Thanki, N., Singh, J., McPhie, P., Zangrilli, D., Wang, L. M., Guerrero, C., LeVine, H., Humblet, C., Saldanha, J., et al. (1995) Biochemistry 34, 9111-9117[Medline] [Order article via Infotrieve]
  49. Runnels, L. W., Jenco, J., Morris, A., and Scarlata, S. (1996) Biochemistry 35, 16824-16832[CrossRef][Medline] [Order article via Infotrieve]
  50. Snyder, J. T., Rossman, K. L., Baumeister, M. A., Pruitt, W. M., Siderovski, D. P., Der, C. J., Lemmon, M. A., and Sondek, J. (2001) J. Biol. Chem. 276, 45868-45875[Abstract/Free Full Text]
  51. Baumeister, M. A., Martinu, L., Rossman, K. L., Sondek, J., Lemmon, M. A., and Chou, M. M. (2003) J. Biol. Chem. 278, 11457-11464[Abstract/Free Full Text]
  52. Philip, F., Guo, Y., and Scarlata, S. (2002) FEBS Lett. 531, 28-32[CrossRef][Medline] [Order article via Infotrieve]
  53. Morreale, A., Venkatesan, M., Mott, H. R., Owen, D., Nietlispach, D., Lowe, P. N., and Laue, E. D. (2000) Nat. Struct. Biol. 7, 384-388[CrossRef][Medline] [Order article via Infotrieve]
  54. Mott, H. R., Owen, D., Nietlispach, D., Lowe, P. N., Manser, E., Lim, L., and Laue, E. D. (1999) Nature 399, 384-388[CrossRef][Medline] [Order article via Infotrieve]
  55. Abdul-Manan, N., Aghazadeh, B., Liu, G. A., Majumdar, A., Ouerfelli, O., Siminovitch, K. A., and Rosen, M. K. (1999) Nature 399, 379-383[CrossRef][Medline] [Order article via Infotrieve]
  56. Kim, O., Yang, J., and Qiu, Y. (2002) J. Biol. Chem. 277, 30066-30071[Abstract/Free Full Text]
  57. Vetter, I. R., Nowak, C., Nishimoto, T., Kuhlmann, J., and Wittinghofer, A. (1999) Nature 398, 39-46[CrossRef][Medline] [Order article via Infotrieve]
  58. Blomberg, N., Baraldi, E., Nilges, M., and Saraste, M. (1999) Trends Biochem. Sci. 24, 441-445[CrossRef][Medline] [Order article via Infotrieve]